farnesol has been researched along with Carcinoma, Hepatocellular in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balaraman, G; Krishnan, P; Mari, A; Salam, S; Sirajduddin, I; Subramaniam, N; Sundaram, J; Thiruvengadam, D | 1 |
| Khuda-Bukhsh, AR; Mondal, J | 1 |
| Chen, Y; Cheng, W; Dong, J; Jing, H; Liang, X; Liu, J; Shang, H; Wang, C; Wang, D; Wu, B; Yuan, Y; Zhou, Y | 1 |
| Chen, T; Pang, Y; Qin, G; Wang, X; Wu, L; Wu, S; Xi, G | 1 |
| Abarca, J; Borbath, I; Charette, N; De Saeger, C; Horsmans, Y; Leclercq, I; Schneider-Merck, T; Stärkel, P | 1 |
| Charette, N; De Saeger, C; Horsmans, Y; Lannoy, V; Leclercq, I; Stärkel, P | 1 |
| Ji, H; Lai, Y; Ling, Y; Peng, S; Tian, J; Ye, X; Zhang, Y; Zhang, Z | 1 |
| Borbath, I; Stärkel, P | 1 |
| Ji, H; Ling, Y; Tang, J; Yang, L; Zhang, Y; Zhang, Z; Zhao, Q | 1 |
| Charette, N; De Saeger, C; Horsmans, Y; Leclercq, I; Stärkel, P | 1 |
10 other study(ies) available for farnesol and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Farnesol alleviates diethyl nitrosamine induced inflammation and protects experimental rat hepatocellular carcinoma.
Topics: Animals; Antioxidants; Carcinoma, Hepatocellular; Diethylnitrosamine; Farnesol; Inflammation; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Oxidative Stress; Rats; Rats, Wistar | 2021 |
Cisplatin and farnesol co-encapsulated PLGA nano-particles demonstrate enhanced anti-cancer potential against hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Synergism; Farnesol; Humans; Liver Neoplasms; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Reactive Oxygen Species | 2020 |
Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Diathermy; Disease Models, Animal; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; ras Proteins; Salicylates; Sequence Analysis, RNA | 2021 |
Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Artemisinins; Carcinoma, Hepatocellular; Drug Synergism; Farnesol; Hep G2 Cells; Humans; Liver Neoplasms; Salicylates | 2017 |
The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Diethylnitrosamine; Farnesol; Gene Expression Regulation, Neoplastic; Genes, ras; Hepatocytes; Immunohistochemistry; Liver Neoplasms; Male; Models, Animal; Rats; Rats, Wistar; Salicylates | 2009 |
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Hep G2 Cells; Humans; Inhibitor of Apoptosis Proteins; Insulin-Like Growth Factor II; Liver Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Salicylates; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitric Oxide Donors; Oxadiazoles; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Salicylates; Stereoisomerism; Structure-Activity Relationship; Toxicity Tests, Acute; Transplantation, Heterologous | 2011 |
Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Farnesol; Humans; Hypoglycemic Agents; Liver Neoplasms; Peptides, Cyclic; Pioglitazone; Salicylates; Somatostatin; Thiazolidinediones | 2011 |
ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Enzyme Activation; Farnesol; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred ICR; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Nitric Oxide; Oxadiazoles; Salicylates | 2011 |
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase 8; Caspase 9; Cell Line, Tumor; Farnesol; Hep G2 Cells; Hepatocytes; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mitochondria; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Salicylates; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2013 |